The University of Southampton
University of Southampton Institutional Repository

Transient response to imatinib in an atypical chronic myeloproliferative disease associated with ins(9;4)(q34;q21q31) and a CDK5RAP2-PDGFRA fusion gene

Walz, Christoph, Schultheis, Beate, Metzgeroth, Georgia, Schoch, Claudia, Curtis, Claire, Lengfelder, Eva, Haferlach, Torsten, Berger, Ute, Hochhaus, Andreas, Hehlmann, Rüdiger, Cross, Nicholas C.P. and Reiter, Andreas (2005) Transient response to imatinib in an atypical chronic myeloproliferative disease associated with ins(9;4)(q34;q21q31) and a CDK5RAP2-PDGFRA fusion gene Blood, 106, (11), p.917A.

Record type: Article


Chronic myeloproliferative disorders (CMPD) associated with rearrangements of the ‘platelet-derived growth factor receptor A’ (PDGFRA) at chromosome 4q12 are excellent candidates for targeted therapy with imatinib. To date, two fusion genes involving PDGFRA have been described: FIP1L1-PDGFRA and BCR-PDGFRA. Here we report a female patient who presented in advanced phase of an atypical myeloproliferative disease. Routine cytogenetic analysis revealed an ins(9;4)(q34;q21q31). Although no break was visible at 4q12, FISH analysis with flanking BAC probes indicated that PDGFRA was disrupted. To identify the partner gene we employed 5'-RACE PCR, exploiting the fact that all known PDGFRA fusions involve exon 12 of this gene. The resulting PCR-products consisted of 5'-sequences derived from CDK5RAP2 (CDK5 regulatory subunit associated protein 2) located on 9q33 and 3'-sequences derived from PDGFRA. CDK5RAP2 encodes a protein that is believed to be involved in centrosomal regulation. FISH analysis confirmed the co-localization of 5' CDK5RAP2 and 3' PDGFRA sequences. RT-PCR confirmed the in-frame mRNA fusion between exon 13 of CDK5RAP2, a 40-bp insert which was partially derived from PDGFRA intron 11 and a truncated PDGFRA exon 12. No reciprocal fusion transcript could be amplified by RT-PCR. The predicted CDK5RAP2-PDGFRA protein consists of 1003 amino acids and retains both tyrosine kinase domains of PDGFRA and several potential dimerisation domains of CDK5RAP2 suggesting a mechanism of tyrosine kinase activation similar to BCR-ABL. Treatment with 400 mg imatinib was initiated and the patient achieved a complete cytogenetic and molecular remission. However, hematological response was only partial with residual blasts repeatedly detectable in the blood and marrow. The patient rapidly developed acute leukemia while still remaining in complete cytogenetic and molecular remission suggesting the outgrowth of a second imatinib-resistant leukemic clone. These findings and the fact that the ins(9;4) was only seen in 24% of metaphases at diagnosis suggests that CDK5RAP2-PDGFRA may have been a secondary abnormality. In summary, we have identified a third fusion gene involving PDGFRA, underlining the fundamental role of activated tyrosine kinases in CMPD’s and their possible response to targeted therapy with imatinib.

Full text not available from this repository.

More information

Published date: 16 November 2005
Additional Information: ASH Annual Meeting Abstracts, Poster Sessions. Abstract 3281.
Keywords: gene, imatinib, germany, time, leukemia, disease, england, hematology


Local EPrints ID: 60390
ISSN: 0006-4971
PURE UUID: 4725ab7a-cbf6-4d16-9df9-6e3207b33a0e
ORCID for Nicholas C.P. Cross: ORCID iD

Catalogue record

Date deposited: 10 Nov 2008
Last modified: 17 Jul 2017 14:23

Export record


Author: Christoph Walz
Author: Beate Schultheis
Author: Georgia Metzgeroth
Author: Claudia Schoch
Author: Claire Curtis
Author: Eva Lengfelder
Author: Torsten Haferlach
Author: Ute Berger
Author: Andreas Hochhaus
Author: Rüdiger Hehlmann
Author: Andreas Reiter

University divisions

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton:

ePrints Soton supports OAI 2.0 with a base URL of

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.